SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of United Therapeutics Corporation (UTHR)

NEW YORK, Feb. 26, 2018

The investigation concerns whether United Therapeutics and certain of its officers and/or directors have violated federal securities laws.

On February 21, 2018, United Therapeutics revealed that because of an increase in the royalty rate the Company is required to pay Eli Lilly for Adcirca under an amended licensed agreement, its cost of product sales have gone up. Following this news, United Therapeutics stock dropped $17.41 per share or roughly 2.9% over the next two trading days to close at $117.55 on February 22, 2018. 

If you are aware of any facts relating to this investigation, or purchased United Therapeutics shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/uthr.   You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com